Aclarion up as data shows cost-effectiveness of its back pain detection system

Aclarion

08/06/2023 13:22

** Shares of healthcare technology co Aclarion Inc  ACON.O 
up 13.5% at $1.2 premarket
    ** Co says abstract on cost-effectiveness highlights its
Nociscan software application statistically dominates
provocative discography test (PD) test because PD is both more
costly and less effective
    ** Nociscan is a software-as-a-service platform, which uses
biomarkers and proprietary augmented intelligence algorithms to
non-invasively help physicians identify the location of chronic
low back pain
    ** "Nociscan can save the U.S. healthcare system from $283M
mln to $441 mln annually," abstract presented on June 3 at a
spine surgery annual meeting highlighted 
    ** PD is a diagnostic test meant to detect pain in the
spinal area
    ** YTD, stock gained 79.3% through Wednesday's close
    

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))